To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill expands funding for pediatric cancer and disease research at the National Institutes of Health. It creates a new funding stream by redirecting civil monetary sanctions (fines, penalties, and disgorgement) collected by the SEC from pharmaceutical companies, dietary supplement producers, and cosmetics manufacturers to the Pediatric Research Initiative Fund. It also increases direct appropriations from $12.6 million in 2024 to $25 million by 2033.
Who Benefits and How
Children with cancer and pediatric diseases benefit from increased research funding that could lead to new treatments and cures. Medical researchers and academic institutions receive expanded grant opportunities through NIH's Pediatric Research Initiative. The National Institutes of Health gains additional resources and clearer coordination authority for pediatric research.
Who Bears the Burden and How
Pharmaceutical companies, dietary supplement manufacturers, and cosmetics companies that violate securities laws (specifically the Foreign Corrupt Practices Act) will have their penalty payments redirected to pediatric research rather than the general Treasury. SEC enforcement actions against these specific industries now have earmarked destinations for collected penalties. There is no direct new regulatory burden; only existing penalties are redirected.
Key Provisions
- Transfers SEC civil monetary sanctions from drug, supplement, and cosmetics companies to the Pediatric Research Initiative Fund
- Increases annual appropriations from $12.6M (2024) to $25M (2033) over 10 years
- Directs NIH to coordinate and prioritize non-duplicative pediatric research
- Requires HHS to report to Congress on pediatric research progress within 4 years
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Expands funding for pediatric disease and cancer research by redirecting SEC civil monetary sanctions from pharmaceutical, dietary supplement, and cosmetics companies to the Pediatric Research Initiative Fund and increasing annual appropriations.
Key Policy Areas
Healthcare, Pediatric Research, Securities Regulation, Government Funding
Primary Purpose
Expands funding for pediatric disease and cancer research by redirecting SEC civil monetary sanctions from pharmaceutical, dietary supplement, and cosmetics companies to the Pediatric Research Initiative Fund and increasing annual appropriations.
Policy Domains
Gabriella Miller Kids First Research Act 2.0
Identified Gains
- Children with pediatric diseases and cancer
- Medical researchers and academic institutions
- National Institutes of Health
Identified Costs
- Pharmaceutical companies violating securities laws
- Dietary supplement companies violating securities laws
- Cosmetics companies violating securities laws
Sponsors
Legislative Progress
ReportedReported by Mr. Sanders, with an amendment and an amendment …
Mr. Kaine (for himself, Mr. Moran, Mr. Heinrich, Mr. Rubio, …
Mr. Kaine (for himself, Mr. Moran, Mr. Heinrich, Mr. Rubio, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Congress (oversight), Department of Health and Human Services, Director of the National Institutes of Health
Positive-direction: Congress (oversight), NIH Pediatric Research Initiative
Negative-direction: Department of Health and Human Services
Medical researchers studying pediatric diseases
Cosmetics manufacturers violating FCPA, Dietary supplement producers violating FCPA, Pharmaceutical manufacturers violating FCPA
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_director"
- → Director of the National Institutes of Health
- "the_secretary"
- → Secretary of Health and Human Services
- "the_commission"
- → Securities and Exchange Commission
- "secretary_of_treasury"
- → Secretary of the Treasury
Key Definitions
Terms defined in this bill
Fund described in section 9008(i)(2) of the Internal Revenue Code of 1986 that receives transfers from SEC sanctions
Persons registered under FDA drug/device registration, or that produce/manufacture/sell/distribute dietary supplements or cosmetics
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology